Recent ALLR News
- Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers • GlobeNewswire Inc. • 05/15/2026 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:03:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 03:48:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 09:20:21 PM
- Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm • GlobeNewswire Inc. • 05/08/2026 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 12:05:42 PM
- Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign • GlobeNewswire Inc. • 05/05/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 09:29:32 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 09:28:37 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:12:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 12:03:59 PM
- Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office • GlobeNewswire Inc. • 04/27/2026 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/27/2026 11:44:40 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 04/24/2026 05:01:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 12:15:32 PM
- Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer • GlobeNewswire Inc. • 04/21/2026 12:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/10/2026 09:18:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 12:54:39 PM
- Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:29:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 01:02:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 01:22:50 PM
- Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization • GlobeNewswire Inc. • 03/06/2026 01:00:00 PM
